2020
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics
SKLADANY, Lubomir, Marian OLTMAN, Sona FRANKOVA, Sylvia DRAZILOVA, Petr HUSA et. al.Základní údaje
Originální název
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics
Autoři
SKLADANY, Lubomir (703 Slovensko), Marian OLTMAN (703 Slovensko, garant), Sona FRANKOVA (203 Česká republika), Sylvia DRAZILOVA (703 Slovensko), Petr HUSA (203 Česká republika, domácí), Jan SPERL (203 Česká republika), Vaclav HEJDA (203 Česká republika), Petr URBANEK (203 Česká republika), Svetlana ADAMCOVA-SELCANOVA (703 Slovensko), Martin JANICKO (703 Slovensko), Pavol KRISTIAN (703 Slovensko), Viera KUPCOVA (703 Slovensko), Marek RAC (203 Česká republika), Ivan SCHRETER (203 Česká republika), Ladislav VIRAG (703 Slovensko), Adriana LIPTAKOVA (703 Slovensko), Miriam ONDRASOVA (703 Slovensko) a Peter JARCUSKA (203 Česká republika)
Vydání
International Journal of Public Health, Basel (Switzerland), Springer, 2020, 1661-8556
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30304 Public and environmental health
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.380
Kód RIV
RIV/00216224:14110/20:00116718
Organizační jednotka
Lékařská fakulta
UT WoS
000576627700002
Klíčová slova anglicky
Chronic HCV infection; HCV genotype; HCV liver disease; Czech Republic; Slovakia; Anti-HCV therapy
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 1. 2021 13:35, Mgr. Tereza Miškechová
Anotace
V originále
Objectives The MOSAIC study gathered data on chronic hepatitis C virus (HCV) infection and its treatment in various countries worldwide. Here we summarise patient and HCV characteristics in the Czech Republic and Slovakia. Methods MOSAIC was an observational study that included patients with chronic HCV infection untreated at the time of enrolment. Study collected and descriptively analysed patient demographics, disease stage and viral characteristics. Data were collected between February 2014 to October 2014. Results Among 220 patients enrolled, 51.4% were treatment-naive. The most prevalent HCV genotype was G1 (78.4%), followed by G3 (19.7%). Higher prevalence of G1 was found in treatment-experienced patients (94.3%) compared to treatment-naive (63.4%). Most participants (67.7%) presented viral RNA load of >= 800,000 IU/mL. Liver cirrhosis was reported in 24.5% of patients. Higher HCV RNA load and duration of HCV infection correlated with the degree of liver fibrosis. Anti-HCV interferon-based treatments were initiated in 88.2% of participants. Conclusions The study confirmed significant changes in the HCV genotypes partition with G3 genotype rapidly increasing in both countries, with possible impact on the WHO eradication initiative and treatment selection.